Multiple clinical trials of the ruxolitinib, a JAK2 inhibitor, are in progress, including trials of the combination of ruxolitinib and nilotinib in patients with CML (ClinicalTrials.gov ID: NCT01702064) and Ph+ acute lymphocytic leukemia (ClinicalTrials.gov ID: NCT02253277). Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.